Claris Bio
PrivateLast Round
Series B
Jul 28, 2026
Est. Valuation
$188M
Total Funding Raised
$175M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Claris Bio is a biotechnology company that specializes in the development of topical formulation technology for the treatment of orphan ophthalmic disorders and corneal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Claris Bio Comparables
Compare Claris Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| iView Therapeutics | 86% | |
| Selagine, Inc. | 82% | |
| Stellular Bio | 81% |
Claris Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 28, 2026 | ||||
| Series A | Jan 4, 2024 |
Claris Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B, Series A |
| RA Capital Management | Series A |
| Mass General Brigham Innovation | Series B, Series A |
| Catalio Capital Management | Series B |
| Novo Holdings | Series B, Series A |
| Aisling Capital | Series B |
| Adage Capital Management | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 125% MoM, reaching 3.5K.
- Aug 20, 2026
Grew 80% QoQ, from 10 to 18 employees.
Recent news
Latest coverage and updates
- closes_offices_inSep 25, 2026
Claris Bio will close offices in Jersey City, New Jersey, United States, Northern America, Americas on Oct 1st '26.
- is_developingSep 25, 2026
Claris Bio will develop CSB-001 on Apr 1st '27.
- hiresAug 3, 2026
Claris Bio hired Marc de Garidel as Chairman of the Board on Aug 3rd '26.
- hiresJul 28, 2026
Claris Bio hires Maha Radhakrishnan as board of directors.
- hiresJul 28, 2026
Claris Bio hired Stephen Brady as chief executive and chief commercial officers on Jul 28th '26.
Claris Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Claris Bio's valuation, stock price, and market status.
Is Claris Bio a public or private company?
Claris Bio is a private company.
What is the current stock price of Claris Bio?
Claris Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Claris Bio worth (valuation)?
Valuation information for Claris Bio is not publicly available.
Can I buy Claris Bio stock?
Claris Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Claris Bio's last funding round?
Claris Bio's most recent funding round was Series A on January 4, 2024.
Who are the main investors in Claris Bio?
Key investors in Claris Bio include Janus Henderson Group, RA Capital Management, Mass General Brigham Innovation, Novo Holdings.
Will Claris Bio IPO soon?
No public IPO plans have been announced for Claris Bio.
How can I track Claris Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Claris Bio's secondary market activity and sign up for updates.